Previous 10 | Next 10 |
Advaxis, Inc. (Nasdaq: ADXS) (the “Company”) , a clinical-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced the closing of its previously announced underwritten public offering of (i) 10,650,000 sh...
Thinly traded nano cap Advaxis ( ADXS -27% ) is down on almost a 7x surge in volume in response to its public offering of 9.2M common shares, common warrants to purchase up to 6.9M shares and ~13.7M pre-funded warrants together with common warrants to purchase up to ~10.2M shares. More...
Advaxis, Inc. (Nasdaq: ADXS) (the “Company”) , a clinical-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced the pricing of an underwritten public offering of (i) 9,200,000 shares of common stock to...
Capricor Therapeutics (NASDAQ: CAPR ) +95% on positive CAP-1002 data . More news on: Capricor Therapeutics, Inc., Galapagos NV, Neon Therapeutics, Inc., Stocks on the move, Read more ...
CD8+ T Cell Reactivity Against 90% of Personalized Neoantigen Targets Confirmed in First of Two Patients Proof-of-Mechanism for Off-the-Shelf ADXS-HOT Program with CD8+ T Cells Against Hotspot Mutations Antigen Spreading Confirmed Advaxis, Inc. (NASDAQ: ADXS), a clini...
Gainers: OMNOVA Solutions (NYSE: OMN ) +55% . SELLAS Life Sciences Group (NASDAQ: SLS ) +46% . Karyopharm Therapeutics (NASDAQ: KPTI ) +36% . One Stop Systems (NASDAQ: OSS ) +26% . NIO (NYSE: NIO ) +15% . Corvus Pharmaceuticals (NASDAQ: CRVS ) +15% . Melinta Therapeutics (NASDA...
Advaxis (NASDAQ: ADXS ) is 6.9% lower after hours following news that it's offering shares through Alliance Global Partners. More news on: Advaxis, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Gainers: TSLA +6.8% . NOG +3.0% . SALT +2.9% . ADXS +2.1% . HEAR +1.9% . More news on: Tesla, Inc., Northern Oil and Gas, Inc., Scorpio Bulkers Inc., Stocks on the move, , News on ETFs Read more ...
Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that it is increasing its focus on neoantigen-directed immunotherapies and closing the AIM2CERV Phase 3 clinical trial w...
Gainers: Sotheby's (NYSE: BID ) +58% . Array BioPharma (NASDAQ: ARRY ) +57% . ContraVir Pharmaceuticals (NASDAQ: CTRV ) +42% . Vislink Technologies (NASDAQ: VISL ) +40% . MTech Acquisition (NASDAQ: MTEC ) +34% . Endurance International Group Holdings (NASDAQ: EIGI ) +26% . C&am...
News, Short Squeeze, Breakout and More Instantly...
MONMOUTH JUNCTION, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that it filed a Form 15 with the Securities and Exchange Commission (the “SEC”) to deregister its common stock under Section 12(g) ...
MONMOUTH JUNCTION, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced the completion of the previously announced sale of AL102, and related drug candidate AL101, to Immunome, Inc. (Nasdaq: IMNM). As per the ...
REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that patient enrollment has been completed in the Phase 3 RINGSIDE study evaluating AL102 in desmoid tumors. A total of 156 ...